The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
de novo myeloma
according to Durie and Salmon classification stage II, III and stage I with a lytic bone lesion
patients from 18 to 65 years old
beta2microglobulin < 3 mg/l or del13 absent
signed informed consent
eligible for transplantation
peripheral neurological toxicities
uncontrolled or severe cardiovascular disease
other malignancy except basocellular carcinoma or FIGO stage I carcinoma of the cervix
patient who received biphosphonate during the last 60 days
renal failure definited as creatinine > 150 µmol/l
patient with obvious vascular cerebral medical history
liver dysfunction definited as bilirubin > 35 µmol/l or ASAT, ALAT, PAL > 4N
Patient who refused to use an acceptable barrier method for contraception